Literature DB >> 10398897

Extended resection for intrahepatic cholangiocarcinoma in Japan.

M Yamamoto1, K Takasaki, T Yoshikawa.   

Abstract

To elucidate surgical outcome after extended surgery for intrahepatic cholangiocarcinoma (ICC), we retrospectively allocated 83 patients who had undergone resection to a standard surgery group (n = 56), in which the patients had undergone hepatectomy alone or hepatectomy with bile duct resection, and an extended surgery group (n = 27), in which the patients had undergone the standard operation combined with vessel resection and/or pancreatectomy. The incidence of mass-forming plus periductal-infiltrating type lesions (P = 0. 0129), lymph node metastasis (P = 0.0005), noncurative resection (P < 0.0001), mortality within 30 days and within 1 year after surgery (P = 0.0392, P = 0.0010), local recurrence (P = 0.0439), and peritoneal disseminated recurrence (P = 0.0241) was significantly higher in the extended surgery group than in the standard surgery group. The 5-year survival rate was significantly higher in the standard surgery group (30%) than in the extended surgery group (10%; P = 0.0061). The mortality rate within 1 year after extended surgery was significantly higher in the patients with infiltrating-spread type tumors than in the patients with non-infiltrating spread type tumors (P = 0.0032), and long-term (5-year) survival in the extended surgery group was significantly lower in the patients with infiltrating-spread type tumors than in the patients with non-infiltrating spread type tumors (P = 0.0253). We conclude that extended surgery does not improve the curative resection rate or the surgical outcome of ICC, and that extended surgery is not indicated for patients with infiltrating-spread type tumors.

Entities:  

Mesh:

Year:  1999        PMID: 10398897     DOI: 10.1007/s005340050093

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  17 in total

1.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.

Authors:  Yuji Morine; Mitsuo Shimada; Tohru Utsunomiya; Satoru Imura; Tetsuya Ikemoto; Jun Hanaka; Mami Kanamoto; Nobuhiro Kurita; Hidenori Miyake
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

2.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

3.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

Review 4.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

Review 5.  The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors:  Yuji Morine; Mitsuo Shimada
Journal:  J Gastroenterol       Date:  2015-04-02       Impact factor: 7.527

Review 6.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 7.  Epidemiology and surgical management of intrahepatic cholangiocarcinoma.

Authors:  Han Zhang; Feng Shen; Jun Han; Yi-Nan Shen; Guo-Qiang Xie; Meng-Chao Wu; Tian Yang
Journal:  Hepat Oncol       Date:  2015-11-30

8.  Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Takahito Nakagawa; Toshiya Kamiyama; Nobuaki Kurauchi; Michiaki Matsushita; Kazuaki Nakanishi; Hirofumi Kamachi; Takeaki Kudo; Satoru Todo
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

9.  Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma.

Authors:  Mustafa Raoof; Sinziana Dumitra; Philip H G Ituarte; Laleh Melstrom; Susanne G Warner; Yuman Fong; Gagandeep Singh
Journal:  JAMA Surg       Date:  2017-05-17       Impact factor: 14.766

10.  [Mesohepatectomy-an alternative to extended hepatectomy in the treatment of central liver tumors].

Authors:  H Lang; G C Sotiropoulos; N R Frühauf; A Radtke; M Malagó; Ch E Broelsch
Journal:  Chirurg       Date:  2004-03-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.